NASDAQ:IMNM Immunome Q1 2025 Earnings Report $25.75 +0.68 (+2.71%) Closing price 04:00 PM EasternExtended Trading$25.87 +0.12 (+0.47%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunome EPS ResultsActual EPS-$0.52Consensus EPS -$0.66Beat/MissBeat by +$0.14One Year Ago EPSN/AImmunome Revenue ResultsActual Revenue$2.93 millionExpected Revenue$0.46 millionBeat/MissBeat by +$2.47 millionYoY Revenue GrowthN/AImmunome Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time12:00AM ETUpcoming EarningsImmunome's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunome Earnings HeadlinesImmunome (NASDAQ:IMNM) Coverage Initiated at Alliance Global PartnersSeptember 21 at 9:06 AM | americanbankingnews.comImmunome, Inc. (NASDAQ:IMNM) Receives $34.64 Consensus Target Price from AnalystsSeptember 17, 2026 | americanbankingnews.comPass by August 7… or wait until 2027?In August, the chairman of the CFTC stood in front of a room in Washington and laid out his marching orders… He said the agency would heed President Trump's call to build a digital asset market structure that "cannot be undone by the crypto haters." Then he told the room he had already directed his staff to begin writing the rules... and most investors completely missed it. And on September 15th, the bill failed. Then something else happened... Three days later, the CFTC filed its own crypto framework with the White House budget office. The SEC already had its rules out for public comment. Both agencies are run by men this president appointed for precisely this purpose. One coin sits at the center of this shift, playing the infrastructure role Uniswap and PancakeSwap played early on, except this one has federal policy pushing behind it.September 22 at 1:00 AM | Crypto 101 Media (Ad)Immunome (NASDAQ:IMNM) Earns Buy Rating from HC WainwrightSeptember 12, 2026 | americanbankingnews.comImmunome, Inc. (IMNM) Latest Press Releases & Corporate News - Yahoo FinanceSeptember 9, 2026 | finance.yahoo.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2026 | businesswire.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development. Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases. Its pipeline and product candidates are subject to ongoing preclinical and clinical evaluation, and the company may collaborate with pharmaceutical and biotechnology partners to advance selected programs. Historically, Immunome applied its human antibody discovery platform to infectious-disease research, including the identification of antibodies against COVID-19. The company has since expanded its focus toward broader therapeutic applications, particularly cancer and immune-related conditions. Immunome is based in the United States and serves global pharmaceutical and healthcare markets through research, development and potential commercialization of its therapies.View Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
